US Stock MarketDetailed Quotes

RAPT RAPT Therapeutics

Watchlist
  • 1.170
  • +0.020+1.74%
Close Feb 26 16:00 ET
154.45MMarket Cap-0.42P/E (TTM)

About RAPT Therapeutics Company

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Company Profile

SymbolRAPT
Company NameRAPT Therapeutics
Listing DateOct 31, 2019
Issue Price12.00
Founded2015
CEODr. Brian Russell Wong, M.D.,PhD
MarketNASDAQ
Employees131
Fiscal Year Ends12-31
Address561 Eccles Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-489-9000
Websitehttp://rapt.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Brian Russell Wong, M.D.,PhD
  • President, Chief Executive Officer and Director
  • 6.59M
  • Rodney Young
  • Principal Accounting Officer, Chief Financial Officer and Secretary
  • 2.18M
  • Dr. William Ho, PhD
  • Chief Medical Officer
  • 1.90M
  • Dirk G. Brockstedt, PhD
  • Chief Scientific Officer
  • --
  • Lori Lyons-Williams
  • Chairman of the Board
  • 262.28K
  • Linda Kozick
  • Independent Director
  • 260.78K
  • Dr. Wendye Robbins, M.D.
  • Independent Director
  • 265.28K
  • Dr. Michael F. Giordano, M.D.
  • Independent Director
  • 267.78K
  • Dr. Mary Ann Gray,PhD
  • Independent Director
  • 277.78K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
WANDA BEARING
920002
+30.00%
HENDERA
831152
+29.97%
LINGOOD
833284
+29.95%
4
WUHAN LAND
830779
+25.43%
5
TECHVISION
832876
+21.28%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!